
INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN BIOLOGY AND MEDICINE

ISSN: 2455-944X

<https://darshanpublishers.com/ijrbm/ijrbmindex.html>

Volume 9, Issue 1 - 2024

Original Research Article

DOI: <http://dx.doi.org/10.22192/ijrbm.2024.09.01.003>

Inflammation-Associated Anemia in Pregnancy: Mechanisms and Clinical Implications

***Emmanuel Ifeanyi Obeagu**

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe

emmanuelobeagu@yahoo.com

Abstract

Inflammation-associated anemia (IAA) is a prevalent and often overlooked condition in pregnancy, arising from a complex interplay between inflammatory responses and iron metabolism disruptions. This review explores the mechanisms by which pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α) inhibit erythropoiesis and alter iron homeostasis, leading to reduced availability of iron for red blood cell production. The clinical implications of IAA are significant, as it can contribute to adverse maternal and fetal outcomes, including increased risk of preterm birth, low birth weight, and maternal morbidity. Pregnant women with underlying inflammatory conditions or nutritional deficiencies are particularly susceptible to developing IAA, highlighting the need for comprehensive screening and individualized management strategies. Addressing nutritional status and controlling inflammation are critical components of effective care.

Keywords: *Inflammation, anemia, pregnancy, cytokines, iron metabolism, maternal health, fetal development.*

Introduction

Anemia during pregnancy is a common public health concern that affects millions of women worldwide. It is defined as a decrease in the number of red blood cells or hemoglobin concentration below normal levels, leading to reduced oxygen-carrying capacity and potential adverse health effects for both the mother and the developing fetus. While iron deficiency anemia (IDA) is the most prevalent form, inflammation-associated anemia (IAA) has emerged as a significant yet often underappreciated contributor to anemia in pregnant women.¹⁻² Pregnancy induces a complex physiological state characterized by increased plasma volume,

heightened metabolic demands, and significant changes in iron requirements. As the body adapts to support the growing fetus, these factors can exacerbate underlying inflammatory conditions or lead to new inflammatory responses. Inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α), play a key role in regulating hematopoiesis and iron metabolism during this period. The elevation of these cytokines can result in decreased red blood cell production and altered iron distribution, leading to the development of IAA.³⁻⁴ The pathophysiology of IAA involves a disruption of the delicate balance between iron homeostasis and erythropoiesis. Pro-inflammatory cytokines stimulate the production of hepcidin, a hormone

that regulates iron absorption and release from stores. Elevated hepcidin levels inhibit intestinal iron absorption and sequester iron in macrophages, creating a functional iron deficiency despite normal iron stores. This mechanism not only compromises red blood cell production but also underscores the complex interaction between the immune system and the hematopoietic process during pregnancy.⁵⁻⁶

In addition to inflammatory processes, nutritional factors significantly influence the development of IAA. Pregnant women with inadequate dietary intake of essential nutrients, such as iron, vitamin B12, and folate, are at an increased risk for anemia. This interplay between inflammation and nutritional deficiencies complicates the diagnosis and management of anemia in pregnancy. Therefore, a thorough understanding of these contributing factors is essential for developing effective screening protocols and targeted interventions.⁷ Clinical implications of IAA extend beyond maternal health; they also impact fetal development and pregnancy outcomes. Anemia in pregnancy is associated with increased risks of preterm birth, low birth weight, and impaired fetal growth. Furthermore, maternal anemia can lead to increased morbidity, including fatigue, decreased quality of life, and heightened susceptibility to infections. Recognizing the role of inflammation in these outcomes is crucial for clinicians to provide comprehensive care that addresses both the mother's and the fetus's needs.⁸⁻⁹

Mechanisms of Inflammation-Associated Anemia

Inflammation-associated anemia (IAA) during pregnancy arises from a complex interplay of immunological responses, iron metabolism dysregulation, and erythropoiesis impairment. Several key mechanisms contribute to the development of IAA, highlighting the multifactorial nature of this condition.¹⁰

1. Cytokine-Mediated Erythropoiesis Suppression:

Inflammatory cytokines play a central role in the development of IAA. Cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF- α), and interleukin-1 (IL-1) are released in response to inflammation and can inhibit erythropoiesis by interfering with erythropoietin production and its action on bone marrow erythroid progenitors. Elevated levels of IL-6, for example, can suppress the secretion of erythropoietin (EPO), the hormone responsible for stimulating red blood cell production. This suppression results in decreased erythrocyte formation, contributing to the anemic state.¹¹

2. Alteration of Iron Homeostasis:

Inflammation significantly disrupts iron metabolism, which is crucial for effective erythropoiesis. During inflammatory responses, cytokines stimulate the liver to produce hepcidin, a key regulator of iron homeostasis. Increased hepcidin levels lead to reduced intestinal absorption of iron and sequestration of iron in macrophages, preventing its availability for hemoglobin synthesis. As a result, even if iron stores are adequate, functional iron deficiency can occur, impairing the production of red blood cells and exacerbating anemia.¹²

3. Impairment of Bone Marrow Function:

Inflammation can directly affect the bone marrow's ability to produce red blood cells. Cytokines and inflammatory mediators can alter the microenvironment of the bone marrow, leading to decreased erythroid progenitor cell proliferation and differentiation. Additionally, chronic inflammation may lead to a shift in hematopoiesis, favoring the production of myeloid cells over erythroid cells, further contributing to the anemia observed in pregnant women.¹³

4. Nutritional Deficiencies:

Nutritional factors are intricately linked to the mechanisms of IAA. Pregnant women are often at risk of deficiencies in essential nutrients, including iron, vitamin B12, and folate, which are

vital for red blood cell production. Inflammation can exacerbate these deficiencies by increasing metabolic demands and altering nutrient absorption and utilization. The combination of inflammatory responses and inadequate nutritional status creates a compounding effect, leading to a more pronounced anemic condition.¹⁴

5. Chronic Diseases and Infections:

Underlying chronic diseases or infections can predispose pregnant women to IAA. Conditions such as autoimmune disorders, chronic kidney disease, or infections like malaria and tuberculosis are associated with elevated inflammatory markers and can contribute to anemia through similar mechanisms. The presence of these conditions amplifies the inflammatory response, leading to further disruptions in erythropoiesis and iron metabolism.¹⁵

6. Interaction with Other Forms of Anemia:

IAA can coexist with other forms of anemia, such as iron deficiency anemia (IDA) and anemia of chronic disease (ACD). The overlapping features of these conditions can complicate diagnosis and treatment. For instance, pregnant women may present with both IAA and IDA due to simultaneous nutritional deficiencies and inflammatory processes. This interplay necessitates a comprehensive evaluation to identify all contributing factors and tailor appropriate interventions.¹⁶

Clinical Implications

Inflammation-associated anemia (IAA) during pregnancy presents significant clinical implications for both maternal and fetal health. Understanding these implications is crucial for healthcare providers to ensure appropriate management strategies are employed to mitigate risks associated with this condition.

1. Maternal Health Risks:

IAA can lead to a range of maternal health issues, including increased fatigue, reduced exercise

tolerance, and compromised immune function. Anemia can exacerbate pre-existing conditions, potentially leading to greater morbidity during pregnancy. Pregnant women with IAA may experience symptoms such as weakness, dizziness, and palpitations, which can significantly impact their quality of life. Additionally, severe anemia can lead to complications such as postpartum hemorrhage, increased risk of infection, and longer recovery times following delivery.¹⁷⁻¹⁸

2. Impact on Fetal Development:

The health of the fetus is closely linked to the mother's hematological status. IAA can have adverse effects on fetal development, including growth restrictions and low birth weight. Anemia in pregnancy has been associated with an increased risk of preterm birth and neonatal complications, such as respiratory distress syndrome and developmental delays. The reduced oxygen-carrying capacity associated with IAA can hinder placental perfusion and fetal oxygenation, potentially leading to long-term consequences for the child's health and development.¹⁹⁻²⁰

3. Increased Risk of Obstetric Complications:

Pregnant women with IAA are at a higher risk for various obstetric complications, including preeclampsia and placental abruption. The inflammatory milieu associated with IAA may contribute to endothelial dysfunction, increasing the risk of hypertensive disorders in pregnancy. Additionally, women with anemia are more likely to experience complications during labor, such as increased blood loss and the need for blood transfusions, which can further complicate maternal and neonatal outcomes.²¹

4. Challenges in Diagnosis and Management:

Diagnosing IAA can be challenging due to overlapping clinical features with other forms of anemia, such as iron deficiency anemia (IDA) and anemia of chronic disease (ACD). Traditional diagnostic approaches that focus solely on

hemoglobin levels may not fully capture the underlying inflammatory processes. Therefore, healthcare providers must adopt a comprehensive diagnostic strategy that includes the evaluation of inflammatory markers, iron studies, and nutritional assessments. This multifaceted approach is essential for accurately diagnosing IAA and developing appropriate management plans.²²⁻²³

5. Need for Targeted Interventions:

The management of IAA in pregnant women requires a tailored approach that addresses the underlying inflammatory processes and nutritional deficiencies. Interventions may include nutritional supplementation with iron, vitamin B12, and folate, alongside treatments to modulate inflammation, such as the use of anti-inflammatory medications when appropriate. Additionally, monitoring and managing any underlying chronic conditions or infections that contribute to inflammation is crucial for effective treatment. Personalized care plans that consider the individual patient's health status, dietary intake, and inflammatory markers can lead to improved maternal and fetal outcomes.²⁴⁻²⁵

6. Public Health Implications:

The prevalence of IAA during pregnancy highlights the need for enhanced public health strategies aimed at preventing and managing anemia in this population. Public health initiatives should focus on increasing awareness of IAA among healthcare providers and pregnant women, promoting routine screening for anemia, and ensuring access to nutritional resources. Education campaigns that emphasize the importance of proper nutrition, regular prenatal care, and early detection of inflammatory conditions can significantly improve maternal and fetal health outcomes. Furthermore, integrating screening for IAA into existing maternal health programs can facilitate timely interventions and reduce the burden of anemia in pregnancy.²⁶

Conclusion

Inflammation-associated anemia (IAA) during pregnancy is a complex and multifaceted condition that poses significant challenges for both maternal and fetal health. The interplay between inflammatory processes, iron metabolism, and nutritional status contributes to the development of IAA, resulting in various clinical implications, including increased morbidity for mothers and adverse outcomes for infants. Recognizing and addressing the mechanisms underlying IAA is essential for effective diagnosis and management, allowing healthcare providers to tailor interventions that meet the unique needs of pregnant women. Effective management of IAA requires a comprehensive approach that includes routine screening for anemia and inflammation, as well as targeted nutritional interventions to address deficiencies in essential vitamins and minerals. Additionally, understanding the broader public health implications of IAA is critical for developing strategies that promote awareness, enhance prenatal care, and ensure access to necessary resources. Public health initiatives should prioritize education and prevention programs that equip pregnant women with knowledge about anemia, its risks, and the importance of maintaining adequate nutrition.

References

1. Owais A, Merritt C, Lee C, Bhutta ZA. Anemia among women of reproductive age: an overview of global burden, trends, determinants, and drivers of progress in low-and middle-income countries. *Nutrients*. 2021; 13(8):2745.
2. World Health Organization. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. 2008.
3. Agree FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. *Journal of Public Health and Nutrition*. 2023;6(1):138.
4. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with


- malaria in Owerri metropolis. *Madonna University journal of Medicine and Health Sciences*. 2022; 2(2):1-9.
5. Means RT. Iron deficiency and iron deficiency anemia: implications and impact in pregnancy, fetal development, and early childhood parameters. *Nutrients*. 2020; 12(2):447.
 6. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. *J Res Med Dent Sci*. 2021 Apr;9(4):145-8.
 7. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*, 2024; 2(3): 38-58
 8. Sapehia D, Mahajan A, Srinivasan R, Kaur J. Prenatal dietary imbalance of folic acid and vitamin B12 deficiency adversely impacts placental development and fetal growth. *Placenta*. 2023; 132:44-54.
 9. Obeagu EI, Obeagu GU. Sickle cell anaemia in pregnancy: a review. *International Research in Medical and Health Sciences*. 2023 Jun 10;6(2):10-3.
 10. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. *Elite Journal of Haematology*. 2024;2(3):67-80.
 11. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. *Int J Curr Res Chem Pharm Sci*. 2016;3(3):10-8.
 12. Muñoz M, Peña-Rosas JP, Robinson S, Milman N, Holzgreve W, Breyman C, Goffinet F, Nizard J, Christory F, Samama CM, Hardy JF. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. *Transfusion medicine*. 2018; 28(1):22-39.
 13. Breyman C. Iron deficiency anemia in pregnancy. In *Seminars in hematology* 2015; 52(4):339-347. WB Saunders.
 14. Green R, Mitra AD. Megaloblastic anemias: nutritional and other causes. *Medical Clinics*. 2017; 101(2):297-317.
 15. Rashid S, Meier V, Patrick H. Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent. *European journal of haematology*. 2021; 106(4):450-455.
 16. Jagnade RS, Bharat R, Singh P. Association Between Systemically Healthy Chronic Periodontitis Pregnant Female Subjects and Anemia of Chronic Diseases: A Clinical Study. *Journal of Advanced Medical and Dental Sciences Research*. 2018;6(9):88-95.
 17. Barrera-Reyes PK, Tejero ME. Genetic variation influencing hemoglobin levels and risk for anemia across populations. *Annals of the New York Academy of Sciences*. 2019; 1450(1):32-46.
 18. Guyatt GH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C. Laboratory diagnosis of iron-deficiency anemia: an overview. *Journal of general internal medicine*. 1992; 7:145-53.
 19. Eweis M, Farid EZ, El-Malky N, Abdel-Rasheed M, Salem S, Shawky S. Prevalence and determinants of anemia during the third trimester of pregnancy. *Clinical Nutrition ESPEN*. 2021;44:194-199.
 20. Agbozo F, Abubakari A, Der J, Jahn A. Maternal dietary intakes, red blood cell indices and risk for anemia in the first, second and third trimesters of pregnancy and at predelivery. *Nutrients*. 2020; 12(3):777.
 21. Siteti MC, Namasaka SD, Ariya OP, Injete SD, Wanyonyi WA. Anaemia in pregnancy: Prevalence and possible risk factors in Kakamega County, Kenya. *Science journal of public health*. 2014;2(3):216-222.
 22. Kumar SB, Arnipalli SR, Mehta P, Carrau S, Ziouzenkova O. Iron deficiency anemia: efficacy and limitations of nutritional and comprehensive mitigation strategies. *Nutrients*. 2022; 14(14):2976.
 23. Pai RD, Chong YS, Clemente-Chua LR, Irwinda R, Huynh TN, Wibowo N, Gamilla MC, Mahdy ZA. Prevention and management of iron deficiency/iron-deficiency anemia in women: an Asian expert consensus. *Nutrients*. 2023; 15(14):3125.
 24. Muñoz M, Peña-Rosas JP, Robinson S, Milman N, Holzgreve W, Breyman C, Goffinet F, Nizard J, Christory F, Samama CM, Hardy JF. Patient blood management in obstetrics: management of

anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. Transfusion medicine. 2018;28(1):22-39.

25. Shi H, Chen L, Wang Y, Sun M, Guo Y, Ma S, Wang X, Jiang H, Wang X, Lu J, Ge L. Severity

of anemia during pregnancy and adverse maternal and fetal outcomes. JAMA network open. 2022;5(2):e2147046-.

26. World Health Organization. Guideline: daily iron and folic acid supplementation in pregnant women. World Health Organization; 2012.

Access this Article in Online	
	Website: www.darshanpublishers.com
	Subject: Hematology
Quick Response Code	

How to cite this article:

Emmanuel Ifeanyi Obeagu. (2024). Inflammation-Associated Anemia in Pregnancy: Mechanisms and Clinical Implications: A Review. Int. J. Curr. Res. Biol. Med. 9(1): 20-25.

DOI: <http://dx.doi.org/10.22192/ijcrbm.2024.09.01.003>